Dec 26, 2006 by Brian Lawler2006 in Review: Vertex PharmaceuticalsThis Rule Breaker has shown how biotech can power a portfolio.
Dec 21, 2006 by Brian LawlerDueling Fools: Merck BullThe blockbusters keep coming from this longtime innovator.
Dec 21, 2006 by Brian LawlerDueling Fools: Merck Bull RebuttalPlenty of cash. Big pipeline. Not to worry.
Dec 21, 2006 by Brian LawlerA Vote of Confidence in ExelixisIt signs another drug development deal with Bristol-Myers.
Dec 20, 2006 by Brian LawlerPDL Rejects an OrphanThe pharmaceutical dismisses a former partner after a failed drug trial.
Dec 19, 2006 by Brian LawlerMelt a Penny, Go to JailThe U.S. Mint has passed new regulations that make melting pennies and nickels illegal.
Dec 18, 2006 by Brian LawlerNaughty: Some Government OfficialsCertain legislators should expect coal-filled stockings.
Dec 18, 2006 by Brian LawlerNice: Flamel's Drug ApprovalForget last year. One FDA approval has changed everything.
Dec 15, 2006 by Brian LawlerReformatting EncysiveYet another delay from the FDA leaves investors hanging.
Dec 14, 2006 by Brian LawlerVertex: Coming Together NicelyPromising trials for a hepatitis C treatment bode well for the pharmaceutical.
Dec 14, 2006 by Brian LawlerCelgene Faces a Generic ChallengeBarr wants to market a version of Thalomid, Celgene's top drug.
Dec 11, 2006 by Brian LawlerAnother Go for Encysive Drug TrialsThis new blood pressure treatment has been developed in fits and starts.
Dec 11, 2006 by Brian LawlerAcorda Calls for 2 More TrialsIt'll be awhile before the FDA makes its decision and the stock price settles down.
Dec 11, 2006 by Brian LawlerBiovail Gives Investors the CashThe company's dividend yield for next year is an eye-popping 9.2%.
Dec 11, 2006 by Brian LawlerWeighing In on Sanofi's AcompliaPositive study results are a load off the company's mind.
Dec 11, 2006 by Brian LawlerRoche's Early Present to HalozymeHappy Holidays! Have some drug-enhancing technology.
Dec 8, 2006 by Brian LawlerMini-Tenders, Big HeadachesNot all tender offers are cause for shareholder excitement.
Dec 8, 2006 by Brian LawlerMedarex Takes the Fast RouteMedarex's lead drug gets an important yet expected designation from the FDA.
